JP2014507144A5 - 慢性ｂ型肝炎感染症のための酵母系免疫療法組成物 - Google Patents
慢性ｂ型肝炎感染症のための酵母系免疫療法組成物 Download PDFInfo
- Publication number
- JP2014507144A5 JP2014507144A5 JP2013553534A JP2013553534A JP2014507144A5 JP 2014507144 A5 JP2014507144 A5 JP 2014507144A5 JP 2013553534 A JP2013553534 A JP 2013553534A JP 2013553534 A JP2013553534 A JP 2013553534A JP 2014507144 A5 JP2014507144 A5 JP 2014507144A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- hbv
- yeast
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 240000004808 Saccharomyces cerevisiae Species 0.000 title claims 22
- 238000009169 immunotherapy Methods 0.000 title claims 10
- 208000000419 Chronic Hepatitis B Diseases 0.000 title 1
- 208000002672 Hepatitis B Diseases 0.000 title 1
- 108009000423 Hepatitis B infection Proteins 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 23
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims 21
- 239000000427 antigen Substances 0.000 claims 18
- 102000038129 antigens Human genes 0.000 claims 18
- 108091007172 antigens Proteins 0.000 claims 18
- 102000037240 fusion proteins Human genes 0.000 claims 13
- 108020001507 fusion proteins Proteins 0.000 claims 13
- 230000001024 immunotherapeutic Effects 0.000 claims 8
- 101710043203 P23p89 Proteins 0.000 claims 5
- 108010008411 hepatitis B virus X protein Proteins 0.000 claims 5
- 235000003534 Saccharomyces carlsbergensis Nutrition 0.000 claims 3
- 229940081969 Saccharomyces cerevisiae Drugs 0.000 claims 3
- 230000028993 immune response Effects 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
Claims (27)
- 免疫療法組成物であって、
ａ）酵母ビヒクル、および
ｂ）ＨＢＶ抗原を含む融合タンパク質であって、前記ＨＢＶ抗原は、
ｉ）配列番号１３０の１位〜６０位と少なくとも９０％同一であるアミノ酸配列を有するＨＢＶ Ｘ抗原と、
ｉｉ）配列番号１３０の６３位〜４６１位と少なくとも９０％同一であるアミノ酸配列を有するＨＢＶ表面抗原と、
ｉｉｉ）配列番号１３０の４６２位〜６４３位と少なくとも９０％同一であるアミノ酸配列を有するＨＢＶコア抗原とからなる融合タンパク質
を含み、
前記組成物はＨＢＶ特異的免疫応答を誘発し、前記融合タンパク質は酵母ビヒクルによって発現される、免疫療法組成物。 - ＨＢＶ抗原は、融合タンパク質中においてＮ末端からＣ末端へ以下すなわち：ＨＢＶ Ｘ抗原、ＨＢＶ表面抗原、ＨＢＶコア抗原、の順序に配置されている、請求項１に記載の免疫療法組成物。
- ＨＢＶ抗原は、配列番号１３０と少なくとも９０％同一であるアミノ酸配列からなる、請求項１に記載の免疫療法組成物。
- 融合タンパク質は、配列番号１３０のアミノ酸配列を含む、請求項１に記載の免疫療法組成物。
- 融合タンパク質は、配列番号１５０のアミノ酸配列を含む、請求項１に記載の免疫療法組成物。
- 融合タンパク質は、配列番号１５０のアミノ酸配列からなる、請求項１に記載の免疫療法組成物。
- ＨＢＶ Ｘ抗原のアミノ酸配列が配列番号１３０の１位〜６０位からなる、請求項１に記載の免疫療法組成物。
- ＨＢＶ表面抗原のアミノ酸配列が配列番号１３０の６３位〜４６１位からなる、請求項１に記載の免疫療法組成物。
- ＨＢＶコア抗原のアミノ酸配列が配列番号１３０の４６２位〜６４３位からなる、請求項１に記載の免疫療法組成物。
- 酵母ビヒクルはサッカロマイセス・セレビシエ（Saccharomyces cerevisiae）に由来する、請求項１に記載の免疫療法組成物。
- 酵母ビヒクルは全酵母である、請求項１に記載の免疫療法組成物。
- 全酵母は加熱不活性化される、請求項１１に記載の免疫療法組成物。
- 全酵母は殺処理される、請求項１１に記載の免疫療法組成物。
- 全酵母は凍結乾燥されたものである、請求項１２に記載の免疫療法組成物。
- 酵母ビヒクルはサッカロマイセス・セレビシエ（Saccharomyces cerevisiae）に由来する、請求項１１に記載の免疫療法組成物。
- 薬学的に許容される賦形剤を含む、請求項１に記載の免疫療法組成物。
- ＨＢＶ抗原を含む融合タンパク質を発現する酵母であって、前記ＨＢＶ抗原は、
ａ）配列番号１３０の１位〜６０位と少なくとも９０％同一であるアミノ酸配列を有するＨＢＶ Ｘ抗原と、
ｂ）配列番号１３０の６３位〜４６１位と少なくとも９０％同一であるアミノ酸配列を有するＨＢＶ表面抗原と、
ｃ）配列番号１３０の４６２位〜６４３位と少なくとも９０％同一であるアミノ酸配列を有するＨＢＶコア抗原とからなる、酵母。 - ＨＢＶ Ｘ抗原のアミノ酸配列が配列番号１３０の１位〜６０位からなる、請求項１７に記載の酵母。
- ＨＢＶ表面抗原のアミノ酸配列が配列番号１３０の６３位〜４６１位からなる、請求項１７に記載の酵母。
- ＨＢＶコア抗原のアミノ酸配列が配列番号１３０の４６２位〜６４３位からなる、請求項１７に記載の酵母。
- ＨＢＶ抗原が配列番号１３０と少なくとも９０％同一であるアミノ酸配列からなる、請求項１７に記載の酵母。
- 融合タンパク質が配列番号１５０のアミノ酸配列からなる、請求項１７に記載の酵母。
- 酵母がサッカロマイセス・セレビシエ（Saccharomyces cerevisiae）に由来する、請求項１７に記載の酵母。
- ＨＢＶ抗原を含む融合タンパク質であって、配列番号１３０または配列番号１５０のアミノ酸配列と少なくとも９０％同一であるアミノ酸配列を含む、融合タンパク質。
- 配列番号１３０と少なくとも９０％同一であるアミノ酸配列を含む、請求項２４に記載の融合タンパク質。
- 配列番号１５０と少なくとも９０％同一であるアミノ酸配列を含む、請求項２４に記載の融合タンパク質。
- 配列番号１５０のアミノ酸配列からなる、請求項２４に記載の融合タンパク質。
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161442204P | 2011-02-12 | 2011-02-12 | |
| US61/442,204 | 2011-02-12 | ||
| US201161496945P | 2011-06-14 | 2011-06-14 | |
| US61/496,945 | 2011-06-14 | ||
| US201161507361P | 2011-07-13 | 2011-07-13 | |
| US61/507,361 | 2011-07-13 | ||
| PCT/US2012/024409 WO2012109404A1 (en) | 2011-02-12 | 2012-02-09 | Yeast-based therapeutic for chronic hepatitis b infection |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015025534A Division JP5911983B2 (ja) | 2011-02-12 | 2015-02-12 | 慢性ｂ型肝炎感染症のための酵母系治療薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014507144A JP2014507144A (ja) | 2014-03-27 |
| JP2014507144A5 true JP2014507144A5 (ja) | 2015-04-02 |
| JP5745102B2 JP5745102B2 (ja) | 2015-07-08 |
Family
ID=46638950
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013553534A Active JP5745102B2 (ja) | 2011-02-12 | 2012-02-09 | 慢性ｂ型肝炎感染症のための酵母系免疫療法組成物 |
| JP2015025534A Active JP5911983B2 (ja) | 2011-02-12 | 2015-02-12 | 慢性ｂ型肝炎感染症のための酵母系治療薬 |
| JP2016068623A Active JP6109989B2 (ja) | 2011-02-12 | 2016-03-30 | 慢性ｂ型肝炎感染症のための酵母系治療薬 |
| JP2017043689A Pending JP2017105834A (ja) | 2011-02-12 | 2017-03-08 | 慢性ｂ型肝炎感染症のための酵母系治療薬 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015025534A Active JP5911983B2 (ja) | 2011-02-12 | 2015-02-12 | 慢性ｂ型肝炎感染症のための酵母系治療薬 |
| JP2016068623A Active JP6109989B2 (ja) | 2011-02-12 | 2016-03-30 | 慢性ｂ型肝炎感染症のための酵母系治療薬 |
| JP2017043689A Pending JP2017105834A (ja) | 2011-02-12 | 2017-03-08 | 慢性ｂ型肝炎感染症のための酵母系治療薬 |
Country Status (24)
| Country | Link |
|---|---|
| US (7) | US8877205B2 (ja) |
| EP (2) | EP2672991B1 (ja) |
| JP (4) | JP5745102B2 (ja) |
| KR (1) | KR102026840B1 (ja) |
| CN (1) | CN103476426B (ja) |
| AP (1) | AP2013007110A0 (ja) |
| AU (2) | AU2012214394B2 (ja) |
| BR (1) | BR112013020425A2 (ja) |
| CA (1) | CA2827150C (ja) |
| CL (1) | CL2013002334A1 (ja) |
| CO (1) | CO6791572A2 (ja) |
| CR (1) | CR20130424A (ja) |
| EA (1) | EA028659B1 (ja) |
| EC (1) | ECSP13012862A (ja) |
| ES (1) | ES2643389T3 (ja) |
| HK (1) | HK1248120A1 (ja) |
| IL (1) | IL227900B (ja) |
| MA (1) | MA34956B1 (ja) |
| PE (1) | PE20140844A1 (ja) |
| SG (1) | SG192285A1 (ja) |
| TW (1) | TWI504608B (ja) |
| UA (1) | UA112859C2 (ja) |
| WO (1) | WO2012109404A1 (ja) |
| ZA (1) | ZA201306481B (ja) |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2651439B1 (en) | 2010-12-17 | 2018-09-19 | Globeimmune, Inc. | Compositions and methods for the treatment or prevention of human adenovirus-36 infection |
| EP3760227A1 (en) | 2011-02-11 | 2021-01-06 | The Trustees of the University of Pennsylvania | Nucleic acid molecule encoding hepatitis b virus core protein and vaccine comprising the same |
| US9238679B2 (en) * | 2011-02-11 | 2016-01-19 | The Trustees Of The University Of Pennslyvania | Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same |
| SG192285A1 (en) | 2011-02-12 | 2013-09-30 | Globeimmune Inc | Yeast-based therapeutic for chronic hepatitis b infection |
| PT2685995T (pt) | 2011-03-17 | 2017-08-09 | Globeimmune Inc | Composições imunoterapêuticas de levedura-brachyury |
| AU2012271625B2 (en) | 2011-06-14 | 2017-05-18 | Globeimmune, Inc. | Yeast-based compositions and methods for the treatment or prevention of hepatitis delta virus infection |
| EP2744918A4 (en) | 2011-08-17 | 2015-06-10 | Globeimmune Inc | IMMUNOTHERAPEUTIC YEAST MUC1 COMPOSITIONS AND USES THEREOF |
| WO2014003853A1 (en) | 2012-06-26 | 2014-01-03 | Biodesix, Inc. | Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies |
| CA2907560C (en) | 2013-03-19 | 2021-12-07 | Timothy C. Rodell | Yeast-based immunotherapy for chordoma |
| EP2978449B1 (en) | 2013-03-26 | 2021-09-08 | Globeimmune, Inc. | Compositions and methods for the treatment or prevention of human immunodeficiency virus infection |
| WO2015031778A2 (en) | 2013-08-30 | 2015-03-05 | Globeimmune, Inc. | Compositions and methods for the treatment or prevention of tuberculosis |
| CA2948803A1 (en) | 2014-04-11 | 2015-10-15 | Globeimmune, Inc. | Yeast-based immunotherapy and type i interferon sensitivity |
| US10507240B2 (en) | 2014-11-28 | 2019-12-17 | Celltrion, Inc. | Epitope of hepatitis B virus surface antigen and binding molecule specifically binding to same for neutralizing hepatitis B virus |
| KR20170102002A (ko) | 2015-01-09 | 2017-09-06 | 이투빅스 코포레이션 | 에볼라 바이러스 백신접종을 위한 방법 및 조성물 |
| HUE038059T2 (hu) | 2015-03-04 | 2018-10-29 | Gilead Sciences Inc | Toll-like receptor moduláló 4,6-diamino-pirido[3,2-D]pirimidin vegyületek |
| US11065313B2 (en) | 2015-08-03 | 2021-07-20 | Globeimmune, Inc. | Modified yeast-brachyury immunotherapeutic compositions |
| EP3341373A1 (en) | 2015-08-26 | 2018-07-04 | Gilead Sciences, Inc. | Deuterated toll-like receptor modulators |
| KR20180100228A (ko) * | 2016-01-12 | 2018-09-07 | 헬름홀츠 젠트룸 뮌헨-도이체스 포르슝스젠트룸 퓌르 게준드하이트 운트 움벨트 게엠베하 | Hbv를 치료하기 위한 수단 및 방법 |
| BR102017010009A2 (pt) | 2016-05-27 | 2017-12-12 | Gilead Sciences, Inc. | Compounds for the treatment of hepatitis b virus infection |
| EP3276006A1 (en) * | 2016-07-27 | 2018-01-31 | Theravectys | Lentiviral vectors for expression of hepatitis b virus (hbv) antigens |
| WO2018045150A1 (en) | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators |
| EP3507276B1 (en) | 2016-09-02 | 2021-11-03 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| CN106421774B (zh) * | 2016-09-08 | 2019-05-28 | 中国科学院生物物理研究所 | PreS1用于制备乙肝疫苗以及治疗慢性乙型肝炎的用途 |
| CN117402852A (zh) | 2016-10-14 | 2024-01-16 | 精密生物科学公司 | 对乙肝病毒基因组中的识别序列特异性的工程化大范围核酸酶 |
| TW202402300A (zh) | 2017-01-31 | 2024-01-16 | 美商基利科學股份有限公司 | 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型 |
| JOP20180008A1 (ar) | 2017-02-02 | 2019-01-30 | Gilead Sciences Inc | مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b |
| GB201705765D0 (en) * | 2017-04-10 | 2017-05-24 | Univ Oxford Innovation Ltd | HBV vaccine |
| JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
| US11471527B2 (en) | 2017-06-05 | 2022-10-18 | Beacle Inc. | Virus-like particles including HBs-L antigen protein for causing immune response against HBV |
| AU2018319538B9 (en) | 2017-08-22 | 2021-05-27 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
| EP3727445B1 (en) * | 2017-12-19 | 2023-08-16 | Janssen Sciences Ireland Unlimited Company | Hepatitis b virus (hbv) vaccines and uses thereof |
| EA202091517A1 (ru) | 2017-12-19 | 2020-11-03 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Способы и устройство для доставки вакцин против вируса гепатита b (hbv) |
| US11020476B2 (en) | 2017-12-19 | 2021-06-01 | Janssen Sciences Ireland Unlimited Company | Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV) |
| KR20200101388A (ko) * | 2017-12-19 | 2020-08-27 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | B형 간염 바이러스 (hbv) 백신의 전달을 위한 방법 및 장치 |
| US11021692B2 (en) | 2017-12-19 | 2021-06-01 | Janssen Sciences Ireland Unlimited Company | Hepatitis B virus (HBV) vaccines and uses thereof |
| US11203610B2 (en) | 2017-12-20 | 2021-12-21 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| CN111566120B (zh) | 2017-12-20 | 2023-09-29 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的3’3’环状二核苷酸 |
| BR112020016466A2 (pt) | 2018-02-13 | 2020-12-15 | Gilead Sciences, Inc. | Composto, composição farmacêutica, métodos para inibir pd-1, pd-l1 e/ou a interação de pd-1/pd-l1, para tratar câncer e para aprimorar a função de células-t em pacientes com hepatite b crônica (chb), e, kit para tratar ou prevenir câncer ou uma doença ou condição. |
| CA3091142C (en) | 2018-02-26 | 2023-04-11 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
| AU2019231652A1 (en) * | 2018-03-06 | 2020-10-01 | Precigen, Inc. | Hepatitis B vaccines and uses of the same |
| WO2019195181A1 (en) | 2018-04-05 | 2019-10-10 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| KR20200140867A (ko) | 2018-04-06 | 2020-12-16 | 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. | 3'3'-사이클릭 다이뉴클레오티드 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| US10899735B2 (en) | 2018-04-19 | 2021-01-26 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| WO2019211799A1 (en) | 2018-05-03 | 2019-11-07 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide |
| EP3793576A4 (en) * | 2018-05-15 | 2022-04-06 | Globeimmune, Inc. | RECOMBINANT YEAST LYSATES FOR INDUCING CELLULAR IMMUNE RESPONSE |
| AU2019297362B2 (en) | 2018-07-06 | 2022-05-26 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
| CN112384283B (zh) | 2018-07-06 | 2023-08-15 | 吉利德科学公司 | 治疗性的杂环化合物 |
| CA3103286C (en) | 2018-07-13 | 2023-05-09 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| AU2019366355B2 (en) | 2018-10-24 | 2022-10-13 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| PE20211655A1 (es) | 2018-10-31 | 2021-08-24 | Gilead Sciences Inc | Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1 |
| TWI721624B (zh) | 2018-10-31 | 2021-03-11 | 美商基利科學股份有限公司 | 經取代之6-氮雜苯并咪唑化合物 |
| US11766447B2 (en) | 2019-03-07 | 2023-09-26 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| JP7350872B2 (ja) | 2019-03-07 | 2023-09-26 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． | ３’３’－環状ジヌクレオチドおよびそのプロドラッグ |
| US20220152078A1 (en) | 2019-03-07 | 2022-05-19 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI826690B (zh) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | 經取代之烯吲哚酮化物及其用途 |
| WO2020254876A1 (en) * | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Virus-like particle delivery of hepatitis b virus (hbv) vaccines |
| CA3140708A1 (en) | 2019-06-18 | 2020-12-24 | Helen Horton | Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives |
| CR20210687A (es) | 2019-06-25 | 2022-03-03 | Gilead Sciences Inc | PROTEÍNAS DE FUSIÓN FLT3L-Fc Y MÉTODOS DE USO |
| WO2021011891A1 (en) | 2019-07-18 | 2021-01-21 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
| WO2021034804A1 (en) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| EP4036111A4 (en) * | 2019-09-27 | 2023-10-25 | Fujirebio Inc. | HEPATITIS B VIRUS CORE ANTIGEN IMMUNOASSAY AND KIT THEREOF |
| JP7398556B2 (ja) | 2019-09-30 | 2023-12-14 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｂｖワクチン及びｈｂｖを治療する方法 |
| CN116057068A (zh) | 2019-12-06 | 2023-05-02 | 精密生物科学公司 | 对乙型肝炎病毒基因组中的识别序列具有特异性的优化的工程化大范围核酸酶 |
| BR112022013620A2 (pt) | 2020-01-09 | 2022-09-13 | Virion Therapeutics Llc | Vetores adenovirais que codificam antígenos virais da hepatite b fundidos à glicoproteína d do vírus do herpes e métodos de uso dos mesmos |
| US20210284716A1 (en) | 2020-03-11 | 2021-09-16 | Immunitybio, Inc. | ACE2-Fc Trap |
| US11857620B2 (en) | 2020-03-11 | 2024-01-02 | Immunitybio, Inc. | Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus |
| CN115605493A (zh) | 2020-03-20 | 2023-01-13 | 吉利德科学公司（Us） | 4′-c-取代的-2-卤代-2′-脱氧腺苷核苷的前药及其制备和使用方法 |
| US20220119426A1 (en) | 2020-08-07 | 2022-04-21 | Gilead Sciences, Inc. | Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| KR20240006683A (ko) | 2021-05-13 | 2024-01-15 | 길리애드 사이언시즈, 인코포레이티드 | TLR8 조절 화합물과 항-HBV siRNA 치료제의 조합물 |
| CN117377671A (zh) | 2021-06-23 | 2024-01-09 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| EP4359389A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CN117355531A (zh) | 2021-06-23 | 2024-01-05 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| WO2023085956A1 (en) * | 2021-11-09 | 2023-05-19 | Avalia Immunotherapies Limited | Novel therapeutic vaccines |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2486400B1 (fr) | 1980-07-09 | 1986-05-30 | Univablot | Medicaments a base de levures ou de leurs extraits insolubles |
| NZ199722A (en) | 1981-02-25 | 1985-12-13 | Genentech Inc | Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain |
| US4775622A (en) | 1982-03-08 | 1988-10-04 | Genentech, Inc. | Expression, processing and secretion of heterologous protein by yeast |
| US5310654A (en) | 1985-07-31 | 1994-05-10 | The Board Of Trustees Of The Leland Stanford Junior University | Method for determining virulence of Yersinia |
| US5164485A (en) | 1985-08-20 | 1992-11-17 | Takeda Chemical Industries, Ltd. | Modified hepatitis B virus surface antigen P31 and production thereof |
| US5234830A (en) | 1988-02-03 | 1993-08-10 | Suntory Limited | DNA encoding a KEX2 endoprotease without a C-terminal hydrophobic region |
| US6306625B1 (en) * | 1988-12-30 | 2001-10-23 | Smithkline Beecham Biologicals, Sa | Method for obtaining expression of mixed polypeptide particles in yeast |
| IL95019A0 (en) | 1989-08-09 | 1991-06-10 | Mycogen Corp | Process for encapsulation of biologicals |
| US6607727B1 (en) * | 1991-08-26 | 2003-08-19 | The Scripps Research Institute | Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus |
| WO1994012617A1 (en) * | 1992-11-25 | 1994-06-09 | International Biotechnology Laboratories, Inc. | Hepatitis b virus vaccines |
| US5413914A (en) | 1993-07-07 | 1995-05-09 | The Regents Of The University Of Colorado | Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases |
| US5830463A (en) | 1993-07-07 | 1998-11-03 | University Technology Corporation | Yeast-based delivery vehicles |
| US5858378A (en) | 1996-05-02 | 1999-01-12 | Galagen, Inc. | Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen |
| JP3713900B2 (ja) | 1996-07-19 | 2005-11-09 | ソニー株式会社 | 負極材料及びこれを用いた非水電解液二次電池 |
| BR9907855A (pt) * | 1998-02-12 | 2001-04-24 | Immune Complex Corp | Conjugado de proteìna de núcleo de hepatite b estrategicamente modificada, partìcula de proteìna, conjugado de partìculas de proteìna, conjugado de proteìna de fusão imunogênica, inóculo, e, processo para induzir anticorpos em um hospedeiro animal |
| WO2001040279A2 (en) * | 1999-12-03 | 2001-06-07 | Innogenetics N.V. | Hbv sequences |
| GB0216074D0 (en) * | 2002-07-11 | 2002-08-21 | Weatherford Lamb | Improving collapse resistance of tubing |
| US20020044948A1 (en) | 2000-03-15 | 2002-04-18 | Samir Khleif | Methods and compositions for co-stimulation of immunological responses to peptide antigens |
| US8153414B2 (en) | 2000-04-06 | 2012-04-10 | Allertein Therapeutics, Llc | Microbial delivery system |
| AU2002225681A1 (en) | 2000-11-15 | 2002-05-27 | Globe Immune, Inc. | Yeast-dentritic cell vaccines and uses thereof |
| CN1171636C (zh) * | 2001-06-06 | 2004-10-20 | 中国人民解放军第二军医大学 | 一种乙型肝炎dna疫苗 |
| US8029803B2 (en) * | 2002-06-20 | 2011-10-04 | Paladin Labs, Inc. | Chimeric antigens for eliciting an immune response |
| US7439042B2 (en) | 2002-12-16 | 2008-10-21 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis C infection |
| KR101455222B1 (ko) | 2002-12-16 | 2014-10-31 | 글로브이뮨 | 면역 요법으로서의 효모계 백신 |
| US8343502B2 (en) | 2002-12-16 | 2013-01-01 | Globeimmune, Inc. | Yeast-based vaccines as immunotherapy |
| EP1609107A4 (en) * | 2003-03-28 | 2006-08-30 | Idm Pharma Inc | METHOD FOR IDENTIFYING OPTIMAL PEPTIDE PITOPARIANTS |
| DE10339927A1 (de) | 2003-08-29 | 2005-03-24 | Rhein Biotech Gesellschaft für neue Biotechnologische Prozesse und Produkte mbH | Zusammensetzung zur Prophylaxe/Therapie von HBV-Infektionen und HBV-vermittelten Erkrankungen |
| EP1809773B1 (en) | 2004-10-18 | 2014-07-16 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis c infection |
| AU2006268333B2 (en) | 2005-07-11 | 2012-06-14 | Globeimmune, Inc. | Compositions and methods for eliciting an immune response to escape mutants of targeted therapies |
| US20070172503A1 (en) | 2005-12-13 | 2007-07-26 | Mycologics,Inc. | Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines |
| SG169375A1 (en) | 2006-02-02 | 2011-03-30 | Globeimmune Inc | Yeast-based vaccine for inducing an immune response |
| WO2007133835A2 (en) | 2006-03-27 | 2007-11-22 | Globeimmune, Inc. | Ras mutation and compositions and mehods related thereto |
| KR100836745B1 (ko) * | 2007-01-31 | 2008-06-10 | (주)두비엘 | Ｈｂｖ 백신 및 그의 제조 방법 |
| WO2008097863A2 (en) | 2007-02-02 | 2008-08-14 | Globeimmune, Inc. | Methods for producing yeast-based vaccines |
| CN101036784B (zh) * | 2007-03-09 | 2010-11-10 | 中国人民解放军第二军医大学 | 一种乙型肝炎治疗性细胞毒性t细胞表位疫苗及其制备方法 |
| RU2505313C2 (ru) | 2007-03-19 | 2014-01-27 | Глоубиммьюн, Инк. | Композиции и способы направленного устранения мутационного ускользания в направленной терапии рака |
| WO2010033841A1 (en) | 2008-09-19 | 2010-03-25 | Globeimmune, Inc. | Immunotherapy for chronic hepatitis c virus infection |
| WO2010065626A1 (en) | 2008-12-02 | 2010-06-10 | Globeimmune, Inc. | Genotyping tools, methods and kits |
| CA2759013C (en) | 2009-04-17 | 2021-10-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Combination immunotherapy compositions against cancer and methods |
| EP2477647B1 (en) | 2009-09-14 | 2016-01-13 | The Regents of the University of Colorado | Modulation of yeast-based immunotherapy products and responses |
| WO2011115914A1 (en) | 2010-03-14 | 2011-09-22 | Globeimmune, Inc. | Pharmacogenomic and response-guided treatment of infectious disease using yeast-based immunotherapy |
| WO2012019127A2 (en) | 2010-08-05 | 2012-02-09 | The Regents Of The University Of Colorado | Combination yeast-based immunotherapy and arginine therapy for the treatment of myeloid-derived supressor cell-associated diseases |
| EP2651439B1 (en) | 2010-12-17 | 2018-09-19 | Globeimmune, Inc. | Compositions and methods for the treatment or prevention of human adenovirus-36 infection |
| SG192285A1 (en) | 2011-02-12 | 2013-09-30 | Globeimmune Inc | Yeast-based therapeutic for chronic hepatitis b infection |
| PT2685995T (pt) | 2011-03-17 | 2017-08-09 | Globeimmune Inc | Composições imunoterapêuticas de levedura-brachyury |
| AU2012271625B2 (en) | 2011-06-14 | 2017-05-18 | Globeimmune, Inc. | Yeast-based compositions and methods for the treatment or prevention of hepatitis delta virus infection |
| EP2744918A4 (en) | 2011-08-17 | 2015-06-10 | Globeimmune Inc | IMMUNOTHERAPEUTIC YEAST MUC1 COMPOSITIONS AND USES THEREOF |
-
2012
- 2012-02-09 SG SG2013060777A patent/SG192285A1/en unknown
- 2012-02-09 ES ES12744328.1T patent/ES2643389T3/es active Active
- 2012-02-09 AP AP2013007110A patent/AP2013007110A0/xx unknown
- 2012-02-09 AU AU2012214394A patent/AU2012214394B2/en active Active
- 2012-02-09 BR BR112013020425A patent/BR112013020425A2/pt not_active IP Right Cessation
- 2012-02-09 WO PCT/US2012/024409 patent/WO2012109404A1/en active Application Filing
- 2012-02-09 EP EP12744328.1A patent/EP2672991B1/en active Active
- 2012-02-09 EP EP17175311.4A patent/EP3266464A3/en not_active Withdrawn
- 2012-02-09 CN CN201280018222.5A patent/CN103476426B/zh active Active
- 2012-02-09 US US13/984,888 patent/US8877205B2/en active Active
- 2012-02-09 JP JP2013553534A patent/JP5745102B2/ja active Active
- 2012-02-09 CA CA2827150A patent/CA2827150C/en active Active
- 2012-02-09 PE PE2013001865A patent/PE20140844A1/es not_active Application Discontinuation
- 2012-02-09 MA MA36222A patent/MA34956B1/fr unknown
- 2012-02-09 EA EA201391170A patent/EA028659B1/ru not_active IP Right Cessation
- 2012-02-09 KR KR1020137024018A patent/KR102026840B1/ko active IP Right Grant
- 2012-02-10 TW TW101104436A patent/TWI504608B/zh active
- 2012-09-02 UA UAA201310911A patent/UA112859C2/uk unknown
-
2013
- 2013-03-13 US US13/798,837 patent/US8722054B2/en active Active
- 2013-08-12 CL CL2013002334A patent/CL2013002334A1/es unknown
- 2013-08-28 ZA ZA2013/06481A patent/ZA201306481B/en unknown
- 2013-08-30 EC ECSP13012862 patent/ECSP13012862A/es unknown
- 2013-08-31 CR CR20130424A patent/CR20130424A/es unknown
- 2013-09-12 CO CO13216900A patent/CO6791572A2/es unknown
- 2013-09-29 IL IL227900A patent/IL227900B/en active IP Right Grant
-
2014
- 2014-02-19 US US14/184,481 patent/US8961988B2/en active Active
- 2014-09-23 US US14/494,235 patent/US9290547B2/en active Active
-
2015
- 2015-01-07 US US14/591,592 patent/US9428556B2/en active Active
- 2015-02-12 JP JP2015025534A patent/JP5911983B2/ja active Active
-
2016
- 2016-03-30 JP JP2016068623A patent/JP6109989B2/ja active Active
- 2016-07-18 US US15/212,930 patent/US9943591B2/en active Active
- 2016-11-10 AU AU2016256751A patent/AU2016256751B2/en active Active
-
2017
- 2017-03-08 JP JP2017043689A patent/JP2017105834A/ja active Pending
-
2018
- 2018-03-01 US US15/909,112 patent/US10441650B2/en active Active
- 2018-06-13 HK HK18107680.0A patent/HK1248120A1/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014507144A5 (ja) | 慢性ｂ型肝炎感染症のための酵母系免疫療法組成物 | |
| JP2012095652A5 (ja) | ||
| JP2012140448A5 (ja) | ||
| JP2016128513A5 (ja) | ||
| JP2015212284A5 (ja) | ||
| JP2012126742A5 (ja) | ||
| JP2014523878A5 (ja) | ||
| JP2009528987A5 (ja) | ||
| JP2015096557A5 (ja) | ||
| JP2012501959A5 (ja) | ||
| EP3266464A3 (en) | Yeast-based therapeutic for chronic hepatitis b infection | |
| JP2013517773A5 (ja) | ||
| JP2011528896A5 (ja) | ||
| JP2014221052A5 (ja) | ||
| JP2013172734A5 (ja) | ||
| EP3199545A3 (en) | Computationally optimized broadly reactive antigens for h1n1 influenza | |
| JP2011530309A5 (ja) | ||
| WO2020132091A9 (en) | Antibodies that neutralize hepatitis b virus and uses thereof | |
| WO2014018858A3 (en) | Multimeric fusion protein vaccine and immunotherapeutic | |
| JP2014530010A5 (ja) | ||
| JP2014503206A5 (ja) | ||
| JP2015524422A5 (ja) | ||
| CA2863949A1 (en) | Computationally optimized broadly reactive antigens for human and avian h5n1 influenza | |
| JP2011528897A5 (ja) | ||
| JP2012532114A5 (ja) |